Reaction
Myeloproliferative Neoplasm reporting signals
As of the last recalculation, Myeloproliferative Neoplasm appears in 646 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is HYDROXYUREA (PRR 82.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Hydroxyurea | 50 | 82.5 | 82.7 |
| Ruxolitinib | 112 | 60.7 | 60.8 |
| Axicabtagene Ciloleucel | 10 | 33.1 | 33.2 |
| Baricitinib | 9 | 30.5 | 30.5 |
| Azacitidine For | 15 | 27.2 | 27.2 |
| Fludarabine Phosphate | 26 | 22.2 | 22.2 |
| Bendamustine Hcl | 10 | 21.1 | 21.1 |
| Imatinib | 10 | 18.5 | 18.6 |
| Azacitidine | 16 | 17.8 | 17.8 |
| Romiplostim | 8 | 17.3 | 17.3 |
| Pemetrexed | 11 | 16.8 | 16.8 |
| Selinexor | 4 | 15.0 | 15.0 |
| Bosutinib | 4 | 14.4 | 14.4 |
| Doxorubicin | 36 | 13.7 | 13.7 |
| Venetoclax | 24 | 13.0 | 13.0 |
| Sarilumab | 7 | 8.6 | 8.6 |